Table 1.
Baseline patient, treatment, and lesion characteristics.
| Patient Characteristic | Patient Cohort (n=75) |
|---|---|
| Mean age at first SRS (yrs) | 62.5 |
| Sex | |
| Male | 51 (68%) |
| Female | 24 (32%) |
| Median KPS | 90 (50-100) |
| Median melanoma-specific GPA | 3 (0-4) |
| History of WBRT before SRS | 5 (7%) |
| Active systemic disease | 61 (81%) |
| Median time from initial melanoma diagnosis to development of BrMets (months) |
37.5 (0-318) |
| BRAF | |
| Mutated | 22 (29%) |
| Wild-type | 30 (40%) |
| Unknown/not tested | 23 (31%) |
| Prior chemotherapy | 18 (24%) |
| BRAF inhibitor | 15 (20%) |
| Immunotherapy type | |
| Anti-CTLA-4 | 54 (72%) |
| Anti-PD-1 | 21 (28%) |
| Lesion Characteristic | Lesion Cohort (n=566) |
| Median lesion volume (mm3) | 105.6 (4-27482) |
| Median dose (Gy) | 20 (12-24) |
| Timing of SRS | |
| Concurrent | 313 (55%) |
| Non-concurrent | 253 (45%) |
| Median length of f/u after SRS (mo) | 6 (1-93) |
Abbreviations: KPS = Karnofsky performance status; GPA = graded prognostic analysis.